Dupilumab, a fully humanized antibody, which inhibits IL-4 and IL-13 by blocking the IL-4 receptor α, is approved for the treatment of atopic dermatitis (AD) and some adverse effects were reported.1,2 Dupilumab facial redness (DFR) is a development of an eczematous facial rash after initiation of dupilumab and is an adverse event not described in the clinical trials. We herein report a case series of DFR to improve clinical knowledge of this possible new adverse event.
展开▼
